4//SEC Filing
MUSSALLEM MICHAEL A 4
Accession 0001225208-24-005500
CIK 0001099800other
Filed
May 1, 8:00 PM ET
Accepted
May 2, 6:05 PM ET
Size
11.4 KB
Accession
0001225208-24-005500
Insider Transaction Report
Form 4
MUSSALLEM MICHAEL A
DirectorChairman & CEO
Transactions
- Exercise/Conversion
Common Stock
2024-05-02$36.75/sh+29,350$1,078,613→ 33,835.82 total - Sale
Common Stock
2024-05-02$85.02/sh−12,207$1,037,839→ 21,628.82 total - Exercise/Conversion
Employee Stock Option (Right to Acquire)
2024-05-02−29,350→ 0 totalExercise: $36.75From: 2017-06-11Exp: 2024-05-10→ Common Stock (29,350 underlying) - Sale
Common Stock
2024-05-02$84.59/sh−17,143$1,450,126→ 4,485.82 total
Holdings
- 4,038,377(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.
- [F2]This transaction was executed in multiple trades at prices ranging from $84.865 to $85.420. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
- [F3]This transaction was executed in multiple trades at prices ranging from $83.860 to $84.860. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Documents
Issuer
Edwards Lifesciences Corp
CIK 0001099800
Entity typeother
Related Parties
1- filerCIK 0001204551
Filing Metadata
- Form type
- 4
- Filed
- May 1, 8:00 PM ET
- Accepted
- May 2, 6:05 PM ET
- Size
- 11.4 KB